AI Summary
This article discusses a phase 2 trial of pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer. The treatment showed antitumour activity and manageable toxicity in patients unresponsive to BCG therapy. It may be a viable option for those who cannot undergo radical cystectomy. However, further research, such as a randomized controlled trial, is needed to confirm these findings.
Pembrolizumab monotherapy showed antitumour activity and manageable toxicity in patients with BCG-unresponsive high-risk Ta or T1 bladder cancer without carcinoma in situ and could potentially be a suitable treatment option for patients who decline or are ineligible for radical cystectomy. Findings will need to be confirmed in a randomised controlled trial.